Navigation Links
Actinium Pharmaceuticals Announces The Addition of The Fred Hutchinson Cancer Research Center To Actinium's Multicenter Clinical Trial For Patients With Acute Myeloid Leukemia
Date:8/1/2012

NEWARK, N.J., Aug. 1, 2012 /PRNewswire/ -- Actinium Pharmaceuticals, Inc. (API), a biopharmaceutical company that develops innovative targeted payload immunotherapeutics, announced that Fred Hutchinson Cancer Research Center has become a clinical site for the Company's ongoing Phase I/II trial in newly diagnosed patients with acute myeloid leukemia (AML).  The trial is designed to establish safety and efficacy of API's drug Actimab-A in AML patients over the age of 60.  Actimab-A treatment consists of the isotope Actinium 225 attached to the anti-CD33 monoclonal antibody lintuzumab (HuM195). 

"We are delighted that The Fred Hutchinson Cancer Research Center joined our trial," said Dr. Dragan Cicic, CEO of Actinium Pharmaceuticals.  "The Fred Hutchinson Cancer Research Center's participation adds another layer to the relationship between our company and this pre-eminent institution and from which we have recently in-licensed BC8, another radiolabeled antibody for treatment of hematologic malignancies, which allowed us to strengthen our product portfolio with a late stage product that has already been in more than 250 patients and continues its development in a number of active trials with impressive results."

Phase I/II multi-center Actimab study will build on the previous phase 1/2 Bismab-A study with a less potent bismuth-213 (Bi-213) isotope and an earlier Actimab-A phase 1 study (where only one dose was administered).  The Phase 2 portion of the Bismab-A study demonstrated efficacy of API's alpha particle platform by producing a number of complete responses in difficult-to-treat relapsed, secondary and poor cytogenetics patients with no standard of care options available. The goal of the current study is to confirm efficacy and safety of Actimab-A, produced by an improved method of manufacture, and to study the effect of multiple doses of treatment.  The population
'/>"/>

SOURCE Actinium Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Actinium Pharmaceuticals Inc. Pays Regulatory Milestone to Abbott Biotherapeutics Corp.
2. Synergy Pharmaceuticals to Present Scientific Posters at the Upcoming Gastroenterology Society Meetings in the U.S. and Europe
3. Inovio Pharmaceuticals Inc. to Webcast, Live, at RetailInvestorConferences.com on August 2nd
4. Nouveau Life Pharmaceuticals (NOUV) Releases Krill Oil to Support Healthy Cholesterol Levels and Reduce Inflammation
5. Kinex Pharmaceuticals Receives Substantial Strategic Investment
6. Auxilium Pharmaceuticals, Inc. Announces Second Quarter 2012 Financial Results
7. Lexicon Pharmaceuticals Reports On Clinical Program Status And 2012 Second Quarter Results
8. Consumers Choosing Organic Alternatives to Traditional Pharmaceuticals
9. Catherine Sohn Elected To Jazz Pharmaceuticals Board Of Directors
10. Stephen G. Austin, CPA Joins Imprimis Pharmaceuticals Board Of Directors
11. Jason Pharmaceuticals, Inc. Reaches Proposed Consent Agreement with FTC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... LAWRENCEVILLE, N.J. , July 24, 2014 /PRNewswire/ ... announced today positive interim data from its ongoing ... Recurrent Chest Wall Breast Cancer (RCWBC).  The trial ... U.S. clinical sites and is evaluating ThermoDox in ... enrolled and treated, 10 were eligible for evaluation of ...
(Date:7/24/2014)... 24, 2014 , Revenues from continuing ... , Adjusted diluted EPS from continuing operations of $1.08, up ... continuing operations of $0.92, 7% below prior year , ... year , Full year 2014 revenues now expected to ... previously , Full year 2014 adjusted diluted EPS range ...
(Date:7/24/2014)... Zimmer Holdings, Inc. (NYSE and SIX: ZMH) ... 30, 2014.  The Company reported second quarter net sales ... 0.9% constant currency over the second quarter of 2013.  ... reported and $1.49 adjusted, an increase of 4.2% adjusted ... second quarter was marked by solid sales growth in ...
Breaking Medicine Technology:Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer 2Celsion Announces Positive Interim Data Update from its Phase 2 DIGNITY Study in Breast Cancer 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 2Quest Diagnostics Reports Second Quarter 2014 Financial Results 3Quest Diagnostics Reports Second Quarter 2014 Financial Results 4Quest Diagnostics Reports Second Quarter 2014 Financial Results 5Quest Diagnostics Reports Second Quarter 2014 Financial Results 6Quest Diagnostics Reports Second Quarter 2014 Financial Results 7Quest Diagnostics Reports Second Quarter 2014 Financial Results 8Quest Diagnostics Reports Second Quarter 2014 Financial Results 9Quest Diagnostics Reports Second Quarter 2014 Financial Results 10Quest Diagnostics Reports Second Quarter 2014 Financial Results 11Quest Diagnostics Reports Second Quarter 2014 Financial Results 12Quest Diagnostics Reports Second Quarter 2014 Financial Results 13Quest Diagnostics Reports Second Quarter 2014 Financial Results 14Quest Diagnostics Reports Second Quarter 2014 Financial Results 15Quest Diagnostics Reports Second Quarter 2014 Financial Results 16Quest Diagnostics Reports Second Quarter 2014 Financial Results 17Quest Diagnostics Reports Second Quarter 2014 Financial Results 18Quest Diagnostics Reports Second Quarter 2014 Financial Results 19Quest Diagnostics Reports Second Quarter 2014 Financial Results 20Quest Diagnostics Reports Second Quarter 2014 Financial Results 21Quest Diagnostics Reports Second Quarter 2014 Financial Results 22Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 2Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 3Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 4Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 5Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 6Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 7Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 8Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 9Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 10Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 11Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 12Zimmer Holdings, Inc. Reports Second Quarter 2014 Financial Results 13
... U.S. District Court Judge Sidney A. Fitzwater has given ... lawsuit that left hundreds of premature babies with life threatening medical conditions and ... will receive compensation under the settlement. , ... "It took years of litigation and research to pry relevant information from people ...
... June 21 One of the leading cancer centers in ... region to introduce fast and efficient RapidArc® radiotherapy treatments from Varian Medical ... treated nine brain cancer, prostate cancer and head & neck cancer patients ... to roll out the technology for many more indications. , ...
Cached Medicine Technology:Fort Worth Attorney Dwain Dent Comments on Final Judgment in Case That Left Hundreds of Babies Dead or Injured 2Al Amal Hospital in Qatar Commences Treatments Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 2Al Amal Hospital in Qatar Commences Treatments Using Fast and Efficient RapidArc Radiotherapy Technology from Varian Medical Systems 3
(Date:7/24/2014)... The first-ever successful isolation and culture of ... been achieved by NFCR-supported scientist Daniel Haber, M.D., Ph.D., ... an important milestone on the road to individualized cancer ... for each patient. , “Tumors evolve in response ... genetic features that make them resistant to drugs. If ...
(Date:7/24/2014)... cancer involves exposing the patient or their tumor more ... X-rays. The radiation damages the cancer cells irreparably. Unfortunately, ... the skin over the site of the tumor, which ... and even skin cancer. As such finding ways to ... in the International Journal of Low Radiation, Faruck Lukmanul ...
(Date:7/24/2014)... Researchers have uncovered a way the malaria parasite ... at Washington University School of Medicine in St. ... including bacterial infections and tuberculosis. , The study ... , Many organisms, including the parasite that causes ... which play multiple roles in keeping organisms healthy, ...
(Date:7/24/2014)... July 24, 2014 July 22, ... in sealant and anesthesia reversal products to National ... help save young smiles. The donation of over ... Oraverse® was distributed to America’s ToothFairy Affiliate clinical ... vital oral health services. The America’s ToothFairy Affiliate ...
(Date:7/24/2014)... (PRWEB) July 24, 2014 Recently, Stwd.co.uk, a ... enriched its product line by adding many new designs of ... All outfits in the new collection come with big discounts. ... launching a special offer on all these fashionable items. They ... example, a pink V-neck strapless beading prom dress was previously ...
Breaking Medicine News(10 mins):Health News:New Blood Test Advances Individualized Cancer Therapy and Cuts Down on Need for Painful Biopsies 2Health News:Natural products from plants protect skin during cancer radiotherapy 2Health News:One route to malaria drug resistance found 2Health News:One route to malaria drug resistance found 3Health News:Septodont Donation Helps Children in Need 2Health News:Cheap Wedding Dresses Are Offered by Stwd.co.uk at Low Prices 2
... , , , SOUTH SAN FRANCISCO, Calif., ... scientific presentations at the International Society on Thrombosis and ... its investigational antiplatelet drug elinogrel, a P2Y(12) ADP receptor ... oral Factor Xa inhibitor anticoagulant antidote in pre-clinical development, ...
... most people sidelined for long, study shows , FRIDAY, July ... full participation in sports or activity within six months of ... , U.S. researchers examined questionnaires filled out by 165 patients, ... performed by a single surgeon between July 1, 2004 and ...
... though, that screenings remain vital , THURSDAY, July 9 (HealthDay ... a screening mammogram is unlikely to ever cause a problem, ... overdiagnosis rate of 35 percent came from an examination of ... researchers and published online Thursday in BMJ . , ...
... (NYSE: WPI ), a leading specialty pharmaceutical company, ... quarter 2009 financial results on Wednesday, July 29, 2009 prior ... Company will also host a conference call and webcast at ... discuss its financial results and provide an update on the ...
... INDIANAPOLIS, July 10 Eli Lilly and Company ... this, its 35th year of support for the Indiana Black Expo (IBE) ... and a presence at the IN Shape Indiana Black ... stay healthy in these uncertain economic times. , , An example ...
... PALM CITY, Fla., July 10 Connectyx Technologies Holdings Group, ... Company is looking to establish itself as the market leader ... by Connectyx CEO, Ronn Schuman during yesterday,s Nationwide Teleconference. ... a goal to reach 1.2 million members by the end ...
Cached Medicine News:Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 2Health News:Portola Pharmaceuticals Announces Several Scientific Presentations at International Society on Thrombosis and Haemostasis XII Congress 3Health News:Shoulder Surgery Helps Athletes Get Back in the Game 2Health News:More Mammograms May Mean More 'Harmless' Cancers 2Health News:Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast 2Health News:Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 2Health News:Lilly Celebrates Its 35th Year as a Supporter of the Indiana Black Expo 3Health News:Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 2Health News:Connectyx Looks to Establish Market Leadership with MedSync and MedFlash Product Line As Stated During Nationwide Teleconference 3
The WellPro 384 is designed for use with 384 well microplates. It utilizes a 24 channel liquid head and can perform serial dilutions in a 16 or 24 across format, and plate to plate transfers and plat...
... 550 compound reformatter performs direct microplate-to-microplate ... nL using a new "touchless" transfer ... Monitoring of acoustic energy reflected from ... 550 to measure the water content ...
... liquid handling capability allows you to ... 5 nanoliters. Precision robotics and flexible ... so youll hit your target every ... without an air gap, providing increased ...
... System Genesis NPS based on the well-known ... to miniaturize your assays for high throughput ... direct dilutions., Furthermore it is an ... gene expression analysis, gene mapping, SNP detection ...
Medicine Products: